Company profile
Ascendis Pharma A/S logo

Ascendis Pharma A/S

Pipeline5 assets

  • TransCon hGHSKYTROFA / growth hormone / TransCon prodrug therapy / Endocrinology Rare Diseases
    Turner syndrome (children aged 1–10)Phase 2United StatesMulti-Indication: Turner syndrome, ISS, SHOX Deficiency, SGA (children aged 2–17)Phase 3MultinationalPediatric GHDPhase 3Japan
  • TransCon CNPC-type natriuretic peptide / TransCon prodrug therapy / Endocrinology Rare Diseases
    Achondroplasia (infants aged 0–<2)Pivotal Phase 2MultinationalAchondroplasia (children aged 2–11)Pivotal Phase 2MultinationalAchondroplasia (adolescents aged 12–18)Pivotal Phase 2bMultinational
  • TransCon CNP + TransCon hGHCNP; growth hormone / TransCon prodrug therapy combination / Endocrinology Rare Diseases
    Achondroplasia (children aged 2–11)Phase 2Multinational
  • TransCon PTHYORVIPATH / parathyroid hormone / TransCon prodrug therapy / Endocrinology Rare Diseases
    Adult Hypoparathyroidism (dosing expansion)Phase 3United StatesAdult HypoparathyroidismPhase 3China
  • TransCon IL-2 β/γ (Systemic)IL-2 β/γ / TransCon prodrug therapy / Oncology
    Various tumor typesPhase 2Multinational

Latest news19 items

All news

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) --

Presentation / Abstract • Phase 3ICCBH 2026 presentation Tue, Jun 30, 2026, 8:30 AM EDT

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th

Presentation / Abstractoral presentation Thu, Jun 25, 2026, 4:01 PM EDT

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today

Trial Results • Phase 3Week 182 data release Sat, Jun 13, 2026, 4:00 PM EDT

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today

Trial Results • Phase 25-Year Phase 2 data readout Thu, Jun 11, 2026, 4:01 PM EDT

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and

Presentation / Abstract • Phase 3Oral presentation Sat, Jun 13, 2026, 2:45 PM CT

Ascendis Pharma Reports First Quarter 2026 Financial Results

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure intended to enable enhanced depth and breadth of

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026 Conference call today at 4:30 pm